This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.This research is sponsored by the American Academy of Child and Adolescent Psychiatry and the National Institute on Drug Abuse. The purpose of this study is to evaluate the effects of the medication dronabinol among adolescents with cannabis use disorders. These disorders, including cannabis abuse and cannabis dependence, involve continued use of marijuana or marijuana-derived substances despite adverse consequences.Subjects will be adolescent who uses marijuana. This study involves six total visits, including four medication sessions. The medication sessions involve administration of dronabinol, which has not been approved by the Food and Drug Administration (FDA) for use in adolescents. The use of dronabinol is investigational for the purpose of this study, meaning that the PI is studying this medication's effects in adolescent marijuana users. Dronabinol currently does not have FDA approval for use in adults or adolescents with cannabis use disorders.
Showing the most recent 10 out of 395 publications
